BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
The BrainSense Adaptive technology is an enhancement to Medtronic’s Percept DBS neurostimulators. The advancement personalizes therapy based on a patient’s brain activity in real-time. Therapy ...
The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode ...